Quanterix is a company that developed the Simoa technology, which can detect single protein molecules in blood samples using arrays of femtoliter-sized wells, providing approximately 1000x greater sensitivity than standard assays like ELISA. Some key points about Quanterix and Simoa:
- Founded in 2007 and is commercializing the Simoa technology through automated instruments and assays for biomarkers related to diseases like cancer, neurological disorders, and inflammation.
- Simoa allows for detection of proteins in the femtomolar to attomolar range from small sample volumes, with precision under 10%, overcoming limitations of other technologies.
- Studies using Simoa have shown potential for early disease detection and monitoring treatment response by measuring
The immunopathogenesis of seropositive rheumatoid arthritisJabed Khan
A presentation on the review article The immunopathogenesis of seropositive rheumatoid arthritis:
from triggering to targeting published in Nature Reviews, Immunology
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
The immunopathogenesis of seropositive rheumatoid arthritisJabed Khan
A presentation on the review article The immunopathogenesis of seropositive rheumatoid arthritis:
from triggering to targeting published in Nature Reviews, Immunology
Large-scale Production of Stem Cells Utilizing MicrocarriersZohaib HUSSAIN
Large-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing MicrocarriersLarge-scale Production of Stem Cells Utilizing Microcarriers
it will help you to understand how the protein microarrays are made, what are the different types and what all purposes they are used for. its very useful ppt
Here is some information about 5 important immunological techniques including Flowcytometry and RIA
I hope it helps and please comment if u come across any mistakes or scope for improvement, it'll really be appreciated.
In this ppt one can know the diiferent softwares and several online servers for the epitope mapping.This mapping helpful for production of different vaccines and antibodies.
B Cell Receptor & Antibody Production-Dr C R MeeraMeera C R
Antibody production is the function of B lymphocytes. These slides describe the structure of B cell receptor and steps involved in antibody production by B lymphocytes
Microarray -types, DNA chip, Principle and application of microarray, Preparation of DNA Chip, Affymetrix chip, microarray in genomics and proteomics, advantages and limitations of microarray
ANTIGEN PROCESSING PRESENTATION AND RECOGNITION - Copy [Autosaved].pptxSamboZailani1
This is a medical students' lecture.
It is among the immunology lectures. it is important for a medical student to understand immunology to some extent.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
it will help you to understand how the protein microarrays are made, what are the different types and what all purposes they are used for. its very useful ppt
Here is some information about 5 important immunological techniques including Flowcytometry and RIA
I hope it helps and please comment if u come across any mistakes or scope for improvement, it'll really be appreciated.
In this ppt one can know the diiferent softwares and several online servers for the epitope mapping.This mapping helpful for production of different vaccines and antibodies.
B Cell Receptor & Antibody Production-Dr C R MeeraMeera C R
Antibody production is the function of B lymphocytes. These slides describe the structure of B cell receptor and steps involved in antibody production by B lymphocytes
Microarray -types, DNA chip, Principle and application of microarray, Preparation of DNA Chip, Affymetrix chip, microarray in genomics and proteomics, advantages and limitations of microarray
ANTIGEN PROCESSING PRESENTATION AND RECOGNITION - Copy [Autosaved].pptxSamboZailani1
This is a medical students' lecture.
It is among the immunology lectures. it is important for a medical student to understand immunology to some extent.
To learn more visit:
https://insidescientific.com/webinar/cutting-edge-conversations-discovering-new-innovations-in-oncology/
Starting off the conversation, Dr. David Bunka will present specific case studies for prostate cancer, multiple myeloma and chronic myelomonocytic leukaemia, highlighting the ability of Optimer technology to deliver novel targeted therapeutics for cancer treatment. Optimer binders are small, highly target specific oligonucleotide-based affinity binders. The Optimer platform offers the ability to develop specific binders targeted to a specific biomarker or to an oncological cell phenotype without the need for known biomarkers. Optimer therapeutics are enabling new strategies in cancer treatment, including the targeted delivery of diverse payloads to cancer cells for precision chemotherapy, or gene therapy approaches.
Dr. Cathie Miller will discuss how archived tissues contain valuable information for clinical research. For over thirty years, BioIVT has worked to expand the characterization of their archived tissues. BioIVT offers complete NGS project management that ensures success. In this presentation, Dr. Miller will review BioIVT’s comprehensive process, their strengths in sample collection through library prep, their in-house and validated partnership capabilities and how BioIVT elevates science.
Finally, Henry Sebesta will introduce KromaTiD’s proprietary technology, Directional Genomic Hybridization™, as an analytical solution for gene & cell therapy oncology treatments. Specifically, Mr. Sebesta will be addressing what Directional Genomic Hybridization is, how it works, and how it can be used to monitor highly important clinical safety metrics including therapeutic vector integration, and genome wide structural rearrangement events.
Accelerating the translation of medical research - 27 JuneInnovation Agency
Slides from the event focusing on translational research in Liverpool and North of England and why companies are establishing and growing operations in the region.
The cure for cancer still eludes us. The next best thing to a cure is the early detection of cancer. In most cases if you detect cancer early enough it can be treated successfully. The holy grail of cancer diagnostics would be a simple blood test with high specificity and sensitivity. VolitionRx (VNRX) is a clinical stage cancer diagnostic company working on a series of blood-based tests for a range of cancers, beginning with Colorectal Cancer (CRC). The company is starting a lucrative 11,000 patient clinical trial in early 2014 to validate their CRC test. The company expects to have multiple data points throughout 2014 and 2015. If early results prove successful, Volition’s current $25 million valuation will likely expand closer to comparables such as Exact Sciences (EXAS) $950 million valuation.
CLinical Research Office at Ponce Health Sciences Foundation/Ponce Research I...Dr. Roberto Torres
The Clinical Research Office at PHSU. Innovating Research and Clinical Trials in Puerto Rico. Learn about our capabilities, Moffitt Cancer Center Collaboration, and the Puerto Rico Clinical Trials Network.
HTS is a high-tech way to hasten the drug discovery process, allowing quick and efficient screening of large compound libraries at a rate of a few thousand compounds per day or per week.
Proteomics Modules designed to bring clinically relevant data, at any point, into the Drug Discovery Process. 1000s of proteins are plated from primary cells and are used to trap autoantibodies from diseased patients' blood sera. Results put a spotlight on highest probability targets.
David Snead on The use of digital pathology in the primary diagnosis of histo...Cirdan
Recent developments in digital pathology enable the rapid scanning of microscope slides at high resolution, making the digitisation of histopathology slides for routine diagnosis purposes feasible. An important initial step in the wider adoption of this technology is the establishment of validation data assessing how effective pathologists are using digital workstations in comparison to conventional light microscopes and glass slides when examining cases for primary diagnosis. I will report on the first study sufficiently powered to demonstrate a statistically valid equivalent (i.e. non-inferior) performance of digital pathology (DP) against standard glass slide (GS) microscopy. This study examined a total of 3,017 cases were included, generating 10,138 slides, which when scanned resulted in a digital archive of 2.45 terabytes. As well as demonstrating non-inferiority of digital in comparison to glass slides the study was useful in establishing rules for slide scanning and identifying areas where digital pathology has limitations and needs to be used with caution.
Finally the presentation covers the impact adopting digital pathology will have on diagnostic laboratories, the economics of these changes and where these changes are most likely to benefit patients.
1. Confidential | 1
Single Molecule Array (Simoa™) for Ultra
High Sensitive Detection of Biomarkers
2. Confidential | 2
Who We Are
Founded in 2007, Quanterix is a leader in high definition diagnostics,
delivering ultrasensitive single molecule measurements for the benefit
of human health.
• Leverages proprietary single molecule array (Simoa™) technology
• Offers ̴1000x sensitivity improvement over current standard
• Proven applications in oncology, neurology, infectious disease, and beyond
3. Confidential | 3
Corporate Overview
• Founded 2007 by David Walt (founder of Illumina) and Nicholas Naclerio
• Exclusive licensee of patent portfolio developed by David Walt at Tufts University
• ̴ 50 employees, 15 Ph.D’s
• Expanded to state-of-the-art 20,000 sq. ft. facility April 2012 in Lexington, MA
• Venture-backed by leading life science investors and strategic partners
• Cumulative $47M Raised in Series A, B, C
4. Confidential | 4
Quanterix is supported by and working with
leading organizations around the world
Investors Partners
Funding Collaborations
6. Confidential | 6
Single Molecule Arrays (Simoa) Provide a Digital Advantage
0 pM 10 pM
• Reaction volume = 100 ×10−6 L
• Diffusion = dilution = low sensitivity
• Millions of molecules needed to reach detection limit
• Reaction volume = 50 ×10−15 L (2 billion times smaller), 50 femtoliters
• Diffusion defeated = single molecule resolution = ultimate sensitivity
• One molecule needed to reach detection limit
Simoa (Digital)
0 aM 3.5 aM 350 aM 3.5 fM
7. Confidential | 7
Step 1. Load Consumables
• Kits
• Cuvettes and disposable tips
• Simoa discs
Step 3. Load Samples
• 96 well plates or tubes
Step 2. Menu Setup
• Select assay
• Calibrators and controls
Step 4. Run Samples
Step 5. Data analysis
• First result in 75 min
Ultra-sensitive with
fully automated
simplicity
Small sample volumes
Open platform
(Homebrew for RUO)
68 test per hour, >500
data points per day
Quanterix Instrument Workflow
8. Confidential | 8
Simoa Disc
• Low-cost consumable
• 24 arrays/disc (4 discs = 96 well
plate)
• 216,000 femtoliter wells per array
• Manufactured using state-of-the
art Blueray™ technology by Sony
DADC
• High volume production easily
scalable 216K wells
9. Confidential | 9
Quanterix Instrument and Assay Features
Metric Quanterix
Throughput • 68 Tests/hour
• >500 data points per day
Workflow • Batch (plates or tubes)
Total Assay Time • <2.5 hours per 96-well plate
Hands on Time • Startup time <20 minutes
• Walkaway time TBD
Automation • Full (sample in to data out)
Sample input • 96-well plates and tubes
Sample volume • 10 ml -100 ml
Instrument Footprint • 135x60x160 cm (freestanding)
Content • 30 Kits at launch
• Homebrew (build your own)
Assay Flexibility • 1, 2 or 3-step assays, incubation time, number of wash steps
Metric Quanterix
Sensitivity • 200 - 1,000 fold better than ELISA
Dynamic range • >4 logs
Precision • <10%
Instrument
Assay
Performance
10. Confidential | 10
Digital ELISA detects proteins in the fg/mL range
Protein
SiMoA LOD
(pg/mL)
Gold Standard
Assay LOD
(pg/mL)
Sensitivity
Fold
Increase
IL-1b 0.001 0.057 R&D Systems 57
TNF-a 0.003 0.106 R&D Systems 35
GM-CSF 0.003 0.26 R&D Systems 87
p24 0.005 5 OCD 1000
IL-6 0.005 0.039 R&D Systems 8
PSA 0.006 10 Roche/Siemens 1667
Ab42 0.02 50 Innotest 2500
tau 0.02 60 Innotest 3000
IL-1a 0.024 1 R&D Systems 42
GLP-1 0.033 11 Luminex 333
p-tau (181 + 231) 0.04 NA NA ND
IL-5 0.049 0.115 R&D Systems 2
Troponin I 0.05 3 Abbott Architect (HS) 60
p-tau-231 0.05 NA NA ND
p-tau-181 0.1 60 Innotest 600
11. Confidential | 11
Simoa Addresses Many Opportunities That Exist for
High Sensitivity Clinical Diagnostics
Infectious Disease
Inflammatory DiseaseOncology
1 mm3 Tumor
BloodBrain
Endothelial Cells
Neurodegenerative Disease
Prenatal Screening
Cardiovascular Disease
Abnormal/
Rare Protein
Simoa allows blood tests for
neurological disorders
Simoa is world’s most sensitive
troponin test
Simoa is first Immunoassay to
be as sensitive to virus as PCR
Simoa first technology to
quantify effect of anti-TNF-a
drugs on target protein
Simoa shortened time for
detection of cancer recurrence
from years to months
12. Confidential | 12
Inflammation
Crohn’s Disease (TNF-a, IL-6) (Mayo Clinic)
• Study Objectives: Measure cytokine levels in normal individuals and patients with clinically
active Crohn’s disease (CDAI>220) undergoing anti-TNFa therapy (e.g. Remicade, Humira,
Enbrel)
• Completed retrospective clinical study on 17 patients.
• Observed significant elevation of IL-6 in plasma from
patients compared to controls. After therapy, the mean
reduction in the concentrations of TNF-a and IL-6 were
46% and 58%, respectively.
• Clinical Utility: Changes in cytokine concentrations after
therapy indicate that measurement using digital ELISA
could be used for monitoring therapeutic efficacy
Song et al., J. Immunol. Methods, 2011, 372, 177-186
0.0
0.5
1.0
1.5
2.0
2.5
3.0
3.5
4.0
4.5
5.0
#1 #3 #5 #11 #13 #17 #19 #25 #27
Case Number
Before treatment with anti-TNF-a
After treatment with anti-TNF-a
TNF-a(pg/mL)
xMAP LOD
Crohn's Disease Healthy
0.01
0.1
1
10
100
[IL-6](pg/mL)
xMAP LOD
Simoa LOD
13. Confidential | 13
Neurology
Brain hypoxia (Ab42, tau) (Univ. of Gothenburg)
• Achieved 2500-3000-fold greater sensitivity than benchmark commercial assays (LOD 10-20
fg/mL). Only test capable of precise measurement of these markers in blood (normally tested
in CSF).
• Completed retrospective clinical study on 25 cardiac arrest patients. Objective: look for
changes in serum levels of these markers as potential early indicators of long term brain
damage.
• Observed, for the first time, Ab42 elevation in live humans
associated with brain ischemia. Suspected significance in
Alzheimer's disease pathogenesis. Strong correlation with 6 month
cognitive outcome. Tau data even stronger.
• Clinical Utility: early prognostic indicators of long term brain
damage.
Zetterberg et al., PLoS ONE 6(12): e28263. doi:10.1371/journal.pone.0028263
good outcome
bad outcome
14. Confidential | 14
AccuPSA(pg/ml)LogScale
0.1
1
10
100
1000
Non-Recurrence Recurrence
Oncology
AccuPSATM (Johns Hopkins, NYU)
• Achieved 1,667-fold greater sensitivity than benchmark commercial assays
(LOD = 6 fg/mL). Only test capable of precise measurement of PSA following
prostatectomy.
• Completed pilot study on utility of the assay to predict recurrence of prostate
cancer after radical prostatectomy from a single blood test.
• Convincingly demonstrated that a single AccuPSA result 3-6 months after
surgery highly predictive of cancer recurrence over five year period.
• Clinical value: ability to target secondary
radiation treatment for higher risk group,
identification of ultra-low risk group for whom
such treatment unnecessary
• Commercial leverage: more accurate treatment
targeting; improved efficacy with earlier
treatment; single test result
• Lepor et al., Br. J. Urol. Int., 2011, 12 OCT 2011, DOI:
10.1111/j.1464-410X.2011.10568.x; Wilson et al., Clin. Chem.,
2011, 57, 1712-1721.
15. Confidential | 15
SimoaTM Benefits
Current Offerings Simoa
Current technologies lack sufficient sensitivity for
many biomarkers
̴ 1000x sensitivity improvement
(femtomolar, 10-15)
Limited dynamic range > 4 logs of dynamic range
Time consuming manual process (3-5 hrs.) Fully automated system – sample in, result out,
save on FTE cost and manual errors
Imprecision High imprecision of results < 10% CVs thanks to digital approach
Large sample size (25-50 microliters) As little at 1 microliter (with dilution)
Acceptable cost/sample Similar costs to current approach, using
conventional reagents
Limited path to Laboratory Developed Tests (LDT)
and IVD
Simoa is very amenable to LDT. Partner in IVD is
bioMerieux
16. Confidential | 16
Using single molecule measurement Simoa
delivers high definition diagnostics. This
remarkable digital sensitivity combined with
full automation unlocks a world of insight into
disease detection, diagnosis, and patient
treatment while meeting the demands of
today’s laboratory.
Thank You